Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

HPV 16 E6/E7-encoding arenavirus vaccine HB-202

A cancer vaccine consisting of replication-attenuated arenavirus encoding the inactivated fusion protein of the viral oncoproteins E6 and E7 derived from the human papillomavirus (HPV) serotype 16, with potential immunomodulating and antineoplastic activities. Upon administration, HPV 16 E6/E7-encoding arenavirus vaccine HB-202 induces expression of the E6/E7 proteins and stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16 E6 and E7, resulting in tumor cell lysis. Oncoproteins E6 and E7 play a key role in the development of cervical intraepithelial neoplasia (CIN) and cervical carcinoma.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:arenavirus vector-based vaccine HB-202
arenavirus vector-based vaccine-expressing HPV 16 E7E6 HB-202
HB-202 cancer vaccine
Code name:HB 202
HB-202
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search